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ABSTRACT55
56
Background 57
It is unknown whether targeted temperature management (TTM) improves survival after 58
paediatric out-of-hospital cardiac arrest (OHCA).  The aim of this study was to assess the 59
evolution, safety and efficacy of TTM (32-34⁰C) compared to standard temperature 60
management (STM) (<38⁰C).61
Methods62
Retrospective, single centre cohort study. Patients aged >one day up to 16 years, admitted to 63
a UK Paediatric Intensive Care Unit (PICU) after OHCA (January 2004 to December 2010). 64
Primary outcome was survival to hospital discharge; efficacy and safety outcomes included:65
application of TTM, physiological, haematological and biochemical side effects. 66
Results67
Seventy three patients were included. Thirty eight patients (52%) received TTM (32-34⁰C).68
Prior to ILCOR guidance adoption in January 2007, TTM was used infrequently (4/25; 16%). 69
Following adoption, TTM (32-34⁰C) use increased significantly (34/48; 71% Chi2 p<0.0001).70
TTM (32-34⁰C) and STM (<38⁰C) groups were similar at baseline. TTM (32-34⁰C) was 71
associated with bradycardia and hypotension compared to STM (<38⁰C). TTM (32-34⁰C) 72
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reduced episodes of hyperthermia (>38⁰C) in the 1st 24 hours; however, excessive73
hypothermia (<32⁰C) and hyperthermia (>38⁰C) occurred in both groups upto 72 hours, and 74
all patients (n=11) experiencing temperature <32⁰C died. The study was underpowered to 75
determine a difference in hospital survival (34% (TTM (32-34⁰C)) vs. 23% (STM (<38⁰C)); 76
p=0.284). However, the TTM (32-34⁰C) group had a significantly longer PICU length of 77
stay.78
Conclusions79
TTM (32-34⁰C) was feasible but associated with bradycardia, hypotension, and increased 80
length of stay in PICU. Temperature <32⁰C had a universally grave prognosis. Larger studies 81
are required to assess effect on survival.82
83
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INTRODUCTION83
It is unknown whether targeted temperature management (TTM) (32-34°C) improves 84
survival and reduces brain injury for infants and children after out-of-hospital cardiac arrest 85
(OHCA) (1). TTM is the active treatment of inducing and maintaining a specific body 86
temperature for a specific duration of time attempting to improve health outcomes (2). 87
Randomized controlled trials in the 2000s renewed interest in 12-24 hours of TTM (32-34°C)88
as a therapeutic intervention in adult survivors of OHCA (3, 4) and for 72 hours in neonates 89
after birth asphyxia (5). The International Liaison Committee on Resuscitation (ILCOR)90
introduced guidance in April 2006 that TTM (32-34°C) may be: 1) beneficial for adolescents 91
who remain comatose following resuscitation from sudden, witnessed, ventricular fibrillation 92
OHCA and 2) considered for infants and children who remain comatose following 93
resuscitation from cardiac arrest (6). More recent adult studies confirm a role for 24 hours of94
TTM but show that a higher temperature target (TTM 36°C) produces similar results to a 95
lower target (TTM 33C) (7). The randomized control trials of Therapeutic Hypothermia 96
after Pediatric Cardiac Arrest (THAPCA studies) of OHCA (NCT00878644) and in-hospital 97
cardiac arrest (NCT00880087) investigating TTM at 33°C for 48 hours versus TTM at 98
36.7°C  are on-going (8, 9).99
Paediatric retrospective studies of TTM have been limited (10-12). Two studies showed no 100
difference in survival outcome with TTM (33-34°C) versus the institutions usual standard 101
temperature management (STM).  The usual STM practice was to maintain normothermia by 102
avoiding hyperthermia (<38°C), but frequently did not involve using active temperature103
control devices (4, 10).These studies included small numbers of OHCA patients and 104
contained very unbalanced groups with regards illness severity, with greater use of TTM (32-105
34) in the more severe group. One recent study from Taiwan did show a statistically 106
significant increase in survival after 72 hours of TTM (33-34°C) (12). However, the OHCA 107
Page 6 of 27
Ac
ce
pte
d M
an
us
cri
pt
6
population was small and differences between healthcare systems may limit generalizability. 108
These studies identified that inadvertent overcooling (<32°C) and hyperthermia (>38°C) 109
increased the risk of worse outcome. 110
The ILCOR TTM (32-34°C) guidance was adopted in our paediatric intensive care unit 111
(PICU) in 2007. TTM (32-34°C) use has developed iteratively and culminated in the use of 112
servo-controlled temperature management devices and a standardized protocol. The aim of 113
this study was to assess evolution, safety and efficacy of TTM (32-34°C) in a tertiary PICU 114
and compare to usual institutional standard temperature management (STM) (aiming to avoid 115
hyperthermia; >38⁰C).116
PATIENTS AND METHODS117
The hospital research committee (Institutional Review Board) approved the study and waived 118
the need for consent given the observational nature of the study. 119
Settings and participants120
This retrospective, single-centre, cohort study included infants and children admitted to the 121
PICU after OHCA between January 2004 and December 2010. Patients were included if aged122
between at least one day and 16 years, admitted to PICU after an OHCA with return of 123
spontaneous circulation (ROSC). OHCA was defined as no cardiac output and pulseless for 124
greater than one minute as confirmed by a trained medical practitioner/paramedic prior to 125
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arrival at an emergency department. Patients were identified via the Paediatric Intensive Care 126
Audit Network (PICANet) (13) and local admission databases.127
Data collection and assessment 128
Case records were reviewed with data-verification at inputting and analysis stage. Patients 129
were divided into two groups, targeted temperature management (TTM 32-34°C) and 130
standard temperature management (STM). The use of TTM was defined a priori as 131
documented active TTM to maintain a core temperature between 32-34°C. STM group 132
included patients whose temperature was maintained at normothermia using rescue 133
temperature controlling measures to avoid hyperthermia (>38°C).134
Data were collected on patient demographics, cardiac arrest resuscitation events, aetiology of 135
arrest, presence of chronic conditions and TTM dosing factors (start time, depth and duration 136
of hypothermia, and length of rewarming) using Utstein defined criteria where available (14).137
Physiological variables were collected including; core temperature, heart rate, systolic blood 138
pressure, partial pressure of carbon dioxide (PaCO2 measured at 37⁰C; alpha-stat 139
method(15)) in the blood, haematological and biochemical parameters. First, we compared 140
values up to four hours post PICU admission for TTM and STM groups to ascertain any 141
differences in risk of mortality. Secondly, the proportions with abnormal values or adverse 142
events within 72 hours of PICU admission were compared. Core temperatures were measured 143
as either rectal, oesophageal or bladder. Episodes of excessive hypothermia were defined as 144
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temperature less than 32°C and hyperthermia greater than 38°C. Adverse events included: 145
seizures, bradycardia (<10th centile for age and sex)(16), hypotension (<5th centile for age and 146
sex)(17), use of critical care organ support and monitoring. The primary outcome was 147
survival at hospital discharge.148
Targeted temperature management149
150
In January 2007, following ILCOR guidance in April 2006, the PICU clinical team151
considered TTM(32-34°C) for OHCA patients on a case by case basis. TTM (32-34°C) was152
initiated in the PICU with the use of servo-controlled water blanket cooling mattresses 153
(Blanketroll II, Cincinnati Sub Zero, Ohio, USA) to reduce temperature between 32 to 34⁰C 154
for 24 hours followed by controlled rewarming, by 0.5⁰C every 2 hours, to 37⁰C.155
Neuromuscular blocking drugs were used to prevent or treat shivering in conjunction with156
intravenous sedation and analgesia (morphine and midazolam). Patients were invasively 157
ventilated with arterial blood gases monitoring. Standard ‘neuroprotective’ PaCO2 target 158
range was 4.5 to 5.0kPa.  Inotropes were used to maintain age appropriate blood pressure. 159
Intracranial pressure monitoring was not used in this population. Clinical neurological 160
assessment and additional neurological monitoring or imaging was performed if required; 161
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however, appropriate, active withdrawal of intensive care occurred following established UK 162
guidelines which do not always require formal ancillary neurological assessment (18). Prior 163
to January 2007, and in patients after 2007 not receiving TTM (32-34°C), STM practice 164
followed recommendations to avoid hyperthermia (>38°C). Initial treatment included165
paracetamol and surface cooling with ice packs, followed by servo-controlled water blanket 166
cooling mattresses (Blanketroll II) if unsuccessful.167
Statistical Analysis168
Descriptive data were reported as median and interquartile range (IQR) or mean ± 95% 169
confidence interval of the mean for continuous variables and as frequencies and percentages 170
for categorical variables. Parametric continuous data were analysed using the unpaired 171
Student t-test and non-parametric continuous data with the Mann Whitney U test or Kruskal-172
Wallis, as appropriate.  Categorical data were analysed using the Fisher’s exact tests. Chi 173
squared trend test was used for change over time.  Two sided p values of <0.05 are reported 174
here. Data analyses were performed using either IBM-SPSS Statistics version 19.0 software 175
(SPSS Inc, Chicago, USA) or Minitab 16 (USA).176
177
RESULTS178
179
Evolution180
Seventy three patients were included, 38 (52%) received TTM (32-34°C) and 35 (48%) STM181
(<38°C). Prior to ILCOR guidance adoption in January 2007, TTM (32-34°C) was used 182
infrequently (4/25; 16%). Following adoption, TTM (32-34°C) use increased significantly 183
and was initiated in 34/48; 71% of patients (p <0.0001, Fig. 1).184
185
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There were no differences in age, sex or weight in patients receiving either treatment (table 186
1). TTM (32-34°C) was used more frequently in patients whose cause of arrest was unknown 187
and less in patients presenting with cardiac arrest associated with trauma (including traumatic 188
brain injury). Prevalence of OHCA occurring in the home or being witnessed was similar for 189
patients receiving TTM (32-34°C) and STM (<38°C) (table 2). However, patients receiving 190
TTM (32-34°C) had significantly more reported episodes of bystander CPR. Only six patients 191
presented in a shockable rhythm (ventricular fibrillation or ventricular tachycardia) and 5 out 192
of 6 received TTM (32-34°C). Total duration of CPR was not significantly different (40 193
minutes (TTM 32-34°C) versus 29 minutes (STM); p=0.23) as was median duration of CPR 194
in the emergency department (12 versus 13 minutes; p=0.98).  A small proportion of cases 195
(3% (TTM) vs. 9% (STM); p=0.24) had ROSC prior to arrival at the emergency department.196
197
198
Safety199
Hyperthermia (>38°C) in the first 24 hours after PICU admission was significantly less 200
frequent in patients receiving TTM (32-34°C)  (1/35; 3%) versus STM (12/32; 38%, 201
p<0.001) (Supplementary APPENDIX tables A1). However, hyperthermia episodes at any 202
point in the first 72 hours post admission were not significantly different (TTM (15/28; 39%) 203
versus STM (14/35; 50%)) (p = 0.46). Five (7%) patients in the study presented to the ED 204
with a temperature below 30°C, of these patients one received TTM (32-34°C) and four STM205
(<38°C). Four patients who received TTM (32-34°C) and two who received STM (<38°C)206
experienced severe hypothermia (temperature <32°C) after arrival to PICU. All eleven 207
patients, with a recorded temperature <32°C from ED admission to 24 hours post PICU208
admission died prior to PICU discharge. 209
210
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More patients receiving TTM (32-34°C) experienced bradycardia (<10th centile for age) (42% 211
versus 19%; p=0.04) and systolic blood pressure (BP) hypotension (<5th centile for age) (63% 212
versus 28%; p=0.004) within 72 hours of admission. No patients required treatment for 213
bradycardia. There was also no statistically significant difference in the proportion of patients 214
receiving inotropic support. (74% vs. 54%; p=0.08). Only one patient in the TTM (32-34°C)215
group received extra corporeal life support (ECLS) for refractory cardiac arrest and 216
rewarming due to profound hypothermia on admission (admission core temperature 14°C).217
218
Lactate, pH, glucose, insulin use, base deficit and the Paediatric Index of Mortality 2 (PIM2) 219
score results were similar between the two treatment groups at PICU admission 220
(Supplementary APPENDIX tables A2). Sixty four percent (41/64) had bilateral 221
unresponsive pupils on PICU admission with no differences noted between treatment groups.222
Similar proportion of patients experienced episodes of seizures (8% versus 14%), 223
thrombocytopenia (36% versus 36%), hypernatremia (24% versus 25%), hypokalaemia (66% 224
versus 46%) and hypomagnesaemia (57% versus 38%) in TTM (32-34°C) and STM (<38°C) 225
groups. Nearly 50% of patients in bo h groups experienced hypocarbia (<4.0kPa).226
227
No patients received renal replacement therapy. MRI and EEG investigations were more 228
common in the TTM (32-34°C) group, although a greater number of MRIs (71%; 17/24) and 229
EEGs (89%; 17/19) were performed after 2007. 230
231
Efficacy232
Patients receiving TTM (32-34°C) were significantly colder during the 24 hours of TTM 233
therapy (Fig. 2). Median temperature at the start of TTM (32-34°C) was 35.0 (IQR [33.8 to 234
36.2])°C. Induction of temperature to target temperature took a median of 02:00 235
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hours:minutes (IQR [0:00 to 03:15]). In those patients with a temperature >35°C at the start 236
of TTM (32-34°C), induction of temperature to target temperature occurred at a median rate 237
of 0.91 (IQR [0.5 to 1.5]) °C/hr. Four patients (11%) had overshoot hypothermia (<32°C) 238
following induction. Median target temperature was 33.4°C and was maintained for a median 239
of 22:30 hours:minutes (IQR [16:37 to 24:44]). Rewarming occurred over a median of 10:30 240
hours:minutes (IQR [07:00 to 14:45]) at a rate of 0.3 (IQR [0.23 to 0.44])°C/hr. Three 241
patients receiving TTM (32-34°C) died prior to rewarming. 242
243
Overall survival to hospital discharge of patients admitted to PICU after OHCA was 29% 244
(21/73) (Table 3). Survival was not significantly different between TTM (32-34°C) and STM 245
(<38°C) treatment groups (34% vs. 23%; p=0.28).  246
TTM (32-34°C) patients stayed in PICU longer compared to STM (<38°C) (Median 4.1 (IQR 247
[3.0 to 6.8] days vs. 1.3 (IQR [0.5 to 6.7]) days; p <0.001). This difference was accounted for 248
by patients dying sooner in the STM (<38°C) group compared with the TTM (32-34°C)249
group (Table 3). There were a similar proportion of patients in both groups who had 250
withdrawal of life sustaining intensive care support prior to death. 251
252
253
254
255
DISCUSSION256
257
The aim of this study was to assess the evolution, efficacy and safety of TTM (32-34°C) in 258
paediatric patients. TTM (32-34°C) use was used frequently in post OHCA patients after the 259
2007 ILCOR guidance. Hospital survival rates were 11% higher in the TTM (32-34°C) group 260
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(34% v 23%; p=0.284) but did not reach statistical significance. The study included patients 261
over a seven year period; however, was underpowered to confirm this difference with 262
certainty. Overall the two groups were comparable across a range of known risk factors  for 263
post cardiac arrest survival except bystander CPR and lower core temperature on PICU264
admission (19). These results are similar to previous reported comparisons of TTM (32-34°C) 265
and usual institutional STM (<38°C) in the paediatric population (10, 11). However, in these 266
studies in contrast to the current study, TTM (32-34°C) was used predominately in patients 267
with a higher predicted risk of mortality and included patients after in-hospital cardiac arrest. 268
269
This study confirms that TTM (32-34°C) is feasible in paediatric patients. TTM (32-34°C)270
was successfully administered in 38 patients. Evidence suggests time to target temperature 271
should be as short as possible, whilst avoiding unintentional overshoot to temperature <32°C272
(20); however, rapid reduction in temperature has also been associated with worse 273
neurological injury (21). Unintentional overshoot in temperature to <32°C occurred in 11% 274
of patients, similar to the 15-17% rate in other retrospective studies (4, 10) but significantly 275
less than the 75% reported by Topjian et al (22). Increased mortality has been reported in 276
subgroups who are overcooled (6) although the causal association has not been established. 277
The use of servo-controlled cooling units, rather than manual temperature control (e.g. ice-278
packs), may account for the reduction in unintentional overshoot. 279
280
Controlled rewarming and the avoidance of overshoot hyperthermia (>38°C) are required to 281
prevent hemodynamic instability, rapid electrolyte changes and worsening of neurological 282
injury (23, 24). Patients were rewarmed at a median rate of 0.3°C/hour, but only 32% re-283
warmed less than or equal to 0.25°C/hour and of concern, 39% experienced hyperthermia. 284
The optimal rewarming rate after TTM (32-34°C) in humans has not been established with a 285
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tendency to decrease rates over the last 10 years (25). Improvements to rewarming strategies 286
and prolonged active control of normothermia may be required to avoid rebound 287
hyperthermia as exposure to hyperthermia in the post-hypothermia phase has also been 288
associated with increased mortality and poor neurological outcome (26).289
290
Reduction in core temperature in humans is known to be associated with a concomitant 291
reduction in heart rate in sedated patients (27). Bradycardia and hypotension is therefore a 292
consistent finding in studies of TTM (32-34°C), irrespective of underlying disease process293
(10, 11, 27). Although bradycardia is believed to not require treatment, the management of 294
hypotension is more controversial. An increase in the proportion of patients with bradycardia 295
and hypotension in the TTM (32-34°C) group was observed. This was associated with 296
increased inotropic support though this did not reach significance. Recently, hypotension in 297
the 1st 6 hours after ROSC in children has been shown to be associated with higher in-298
hospital mortality and worse neurological outcome (28). In the current study hypotension 299
episodes up to 72 hours after ROSC were included. It remains unclear whether the timing of 300
hypotension or the concomitant treatment is important in determining outcome. Certainly, 301
invasive, continuous monitoring of arterial blood pressure is recommended with TTM (32-302
34°C).303
304
A number of findings differed to previously published studies. Seizure frequency was low 305
(11%) with no difference between TTM (32-34°C) or STM (<38°C) groups. Abend et al 306
identified a higher rate of seizures (47%; 9/19) in a prospective study of therapeutic 307
hypothermia in paediatric cardiac arrest patients (29). Formal electroencephalography (EEG) 308
monitoring was performed in only 26% of our patients and may account for the lower rate. 309
Continuous EEG monitoring may allow improved identification and treatment in this 310
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population (30, 31). Hypocarbia (PaCO2 <4kPa) occurred in nearly half of both TTM (32-311
34°C) and STM (<38°C) patients in the first 24 hours of the study potentially exposing 312
patients to cerebral vasoconstriction and cerebral ischemia. Episodes of hypocarbia and/or 313
hypercarbia compared to normocarbia are associated with worse neurological outcome in 314
adult cardiac arrest survivors and should be avoided (32). Continuous end tidal CO2315
monitoring may therefore be beneficial.316
317
TTM (32-34°C) has changed the traditional timing of clinical, electrophysiological and 318
neuro-imaging investigation to predict outcome after hypoxic ischemic brain injury (33-36).  319
Delayed clearance of sedative drugs alters timing for neurological and brain death testing, 320
prolonging PICU length of stay (37). This effect was observed with a four-fold increase in321
PICU length of stay for TTM (32-34°C) patients who eventually died compared to STM non-322
survivors. The inclusion of only OHCA patients may explain the comparative shorter length 323
of stay for STM patients (1.3 days) compared to Doherty et al (11) (9.0 days (IQR [5.0 to 324
22.3])) and Fink et al (10) (5 days (IQR [1 to 14])). A temporal trend of increasing time to 325
withdrawal of intensive care support and death along with an increased use of MRI and EEG 326
investigations was also noted. This may reflect a change in clinical practice when predicting 327
outcome with a delayed assessment and increased use of multi-modal methods of outcome 328
prediction occurring over time. 329
330
The prolonged duration of treatment associated with the TTM (32-34°C) group may reflect 331
an optimistic view of paediatric intensivists for a good outcome following OHCA, influenced332
in part by the positive findings of neonatal and adult TTM (32-34°C) trials (3-5, 7). Twenty 333
four hours of TTM (32-34°C) followed by 12-16 hours rewarming enables a period of active 334
PICU treatment, correction and titration of physiology variables and a delay to neurological 335
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prognosis. This positive approach after OHCA contrasts the historic views of poor outcome 336
despite PICU management and may have postively effected patient outcome.    337
338
Neonatal studies after birth asphyxia have supported the recommendations of TTM (33°C)339
for 72 hours (5). These study populations were carefully selected with a homogenous 340
pathology and severity assessed by predefined stratification criteria. However, the paediatric 341
OHCA population is heterogenous; variable aetiologies, co-morbidities and resuscitation 342
factors limit the ability to extrapolate the neonatal findings to paediatric OHCA.343
344
This study has the following limitations. 1) This is a single centre study and is still relatively 345
small despite a seven year data collection period. 2) Data from a single centre may limit the 346
general applicability of the overall findings to other centres. 3) Owing to the retrospective 347
nature of this study we were unable to separate patients in the STM (<38°C) group who had 348
reactive hyperthermia (>38°C) treatment only and those initiated on an active normothermia 349
targeted temperature management. 4) Changes in clinical management of OHCA may have 350
changed over the study period. It was identified that the use of TTM (32-34°C), neuro-351
imaging and neuro-electrophysiological monitoring increased in the second half of the study352
and there may have been other confounding factors (e.g. new resuscitation guidelines in 353
2005) not identified. 5) The use of TTM (32-34°C) was not randomized with the potential for 354
case selection bias. 6) The primary outcome was hospital survival as neurological outcome 355
data was not available, but should be collected in future studies.356
357
CONCLUSION358
This study assessed the evolution, safety and efficacy of TTM (32-34°C) compared with 359
STM (<38°C) after OHCA. TTM (32-34°C) use increased significantly after ILCOR 2007 360
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guidance. TTM (32-34°C) was effectively administered in the paediatric population but 361
resulted in bradycardia and hypotension. It did not significantly increase survival to hospital 362
discharge but increased PICU length of stay. Avoidance of excess hypothermia (<32°C) is 363
recommended. Further studies are required to demonstrate whether TTM (32-34°C) is cost-364
effective, and improves the proportion of patients with good neurological survival after 365
OHCA.366
367
368
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TABLES & FIGURES374
375
Table 1 Demographics and relationship to treatment groups376
377
Table 2 Cardiac arrest resuscitation factors, PICU interventions and relationship to treatment 378
groups379
Table 3 Survival outcomes in relationship to treatment groups380
381
FIGURES382
383
Figure 1 Percentage of patients receiving targeted temperature management (TTM) and 384
standard temperature therapy (STM) 385
Dashed red line indicates first publication date of ILCOR guidelines for paediatric TTM use: 386
Published on-line April 17th 2006 - “Induction of hypothermia (32 to 34°C) for 12 to 24 387
hours should be considered in children who remain comatose after resuscitation from cardiac 388
arrest.” (38)389
390
Figure 2 Temperature profiles of patients receiving targeted temperature management and 391
standard temperature therapy.392
Mean temperature (with 95% confidence intervals for the mean). TTM: targeted temperature 393
management.  STM: Standard temperature management.394
395
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SUPPLEMENTARY APPENDIX397
Table A1 Adverse events within 72 hours of admission398
Table A2 Physiological variables available between ROSC to four hours after PICU 399
admission and relationship to treatment groups400
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Table 1 Demographics and relationship to treatment groups491
Total Group
n =73
TTM
n=38
STM
n = 35
p
Age (years) 1.0 (0-5.0) 1.5 (0-5.8) 1.0 (0-4.0) 0.74
Weight (kg) 8 (4-15) 10 (6-20) 6 (4-12) 0.06
Age category (Utsteina) 0.57
1-30 days 7 (10%) 5 (13%) 2 (6%)
31 days to < 1 yr 23 (32%) 10 (26%) 13 (38%)
1yr to < 4yrs 21 (29%) 11 (29%) 10 (29%)
4yrs to < 12yrs 9 (13) 4 (11%) 5 (15%)
12yrs to < 16yrs 12 (17%) 8 (21%) 4 (12%)
Male 25 (34%) 17 (45%) 8 (23%) 0.08
Any Chronic Condition 33 (45%) 15 (39%) 18 (51%) 0.30
Neurological 17 (23%) 9 (24%) 8 (23%) 0.93
Respiratory 13 (18%) 7 (18%) 6 (17%) 0.89
Cardiac 4 (5%) 1 (3%) 3 (9%) 0.27
Prematurity 3 (4%) 1(3%) 2 (6%) 0.60
Metabolic 4 (5%) 2 (4%) 2 (3%) 0.71
Gastrointestinal 1 (1%) 1 (3%) 0 1.00
Renal 1 (1%) 0 1 (3%) 1.00
Transported from different 
admitting hospital
37 (51%) 21 (55%) 16 (47%) 0.49
Etiology of arrest
Not Known 12 (16%) 9 (23%) 3 (9%) 0.12
Pulmonary 16 (22%) 9 (24%) 7 (20%) 0.78
Cardiac 5 (7%) 4 (11%) 1 (3%) 0.19
Trauma (including 
traumatic brain injury)
11 (14%) 3 (8%) 8 (23%) 0.10
Drowning/Submersion 6 (8%) 3 (7%) 3 (9%) 1.00
Neurological (non-trauma) 7 (10%) 2 (5%) 5 (14%) 0.25
Sepsis 5 (7%) 2 (5%) 3 (9%) 0.67
Strangulation 3 (4%) 2 (5%) 1 (3%) 1.00
Sudden infant death 
syndrome
2 (3%) 0 2 (5%) 0.23
Other 6 (8%) 4 (11%) 2 (6%) 0.68
a Utstein pre-defined age groups with modified upper age limit to less than 16 years (13)(14). Results expressed 492
as Median (Inter-quartile range) or number (percent). Allocation to multiple chronic conditions was permitted. 493
Fisher’s exact test was used for categorical variable and Mann Whitney U test for continuous variables. 494
495
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495
Table 2 Cardiac arrest resuscitation factors, PICU interventions and relationship to treatment groups496
Cardiac arrest resuscitation 
events
Total Group
n =73
TTM
n=38
STM
n = 35
p
Location own home (versus 
public place or other)
45 (68%) 23 (70%) 22 (67%) 0.79
Witnessed arrest 45 (65%) 23 (62%) 22 (69%) 0.57
Bystander CPR 45 (65%) 30 (81%) 15 (47%) 0.003
VF/VTa (vs. PEA/ 
bradycardia/asystole)
6 (9%) 5 (14%) 1 (3%) 0.20
Pulseless electrical 
activity (PEA)
10 (15%) 6 (17%) 4 (13%)
Bradycardia 7 (6%) 2 (16%) 5 (11%)
Asystole 43 (65%) 22 (63%) 21 (67%)
Ventricular fibrillation (VF) 5 (8%) 5 (14%) 0 (0)
Pulseless Ventricular 
tachycardia (VT)
1 (2%) 0 (0) 1 (3%)
Defibrillation attempted 10 (14%) 7 (18%) 3 (10%) 0.28
Epinephrine doses during 
resuscitationb
3 (1-4) 3 (1-4) 3 (1-4) 0.83
No epinephrine given during 
resuscitation
6 (9%) 2 (5%) 4 (13%) 0.40
Time duration from cardiac 
arrest onset to ROSC (mins)
38 (24-49) 40 (26-56) 29 (21-46) 0.23
ROSC prior to ED admission 8 (6%) 2 (3%) 6 (9%) 0.24
Time from ED admission to 
ROSC (mins)c 12 (5-19) 12 (4-20) 13 (8-18) 0.98
Time duration from  ROSC to 
PICU admission (hrs:mins)
02:57
(01:13-04:34)
02:50 
(01:24-04:51)
03:20 
(00:50-04:29)
0.67
PICU interventions
Mechanical ventilation 73 (100%) 38 (100%) 35 (100%) 1.00
Inotropes after resuscitation 47 (64%) 28 (74%) 19 (54%) 0.08
Two or more inotropes 11 (15%) 8 (21%) 3 (9%) 0.19
HFOV 2 (3%) 2 (3%) 2 (3%) 1.00
ECMO 1 (1%) 1 (3%) 0 1.00
Renal replacement therapy 0 0 0
Insulin therapy 19 (26%) 13 (34%) 6 (17%) 0.10
Neuromuscular blockade after 
PICU admission
31 (42%) 16 (42%) 15 (43%) 0.95
Anti-seizure therapy 10 (14%) 6 (16%) 4 (11%) 0.74
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CPR denotes cardiopulmonary resuscitation. ROSC denotes return of spontaneous circulation. ED: emergency 497
department, PICU Paediatric intensive care unit. aFirst recorded rhythm after cardiac arrest. VF: ventricular 498
fibrillation, VT: ventricular tachycardia, PEA: pulseless electrical activity. Unavailable (missing) values were 499
excluded from calculations of summary statistics. Data was missing for location (7), witnessed status (4), 500
Bystander (4), presenting electrical rhythm (7), Defibrillation attempt (6), Epinephrine dose (4), duration from 501
cardiac arrest (5), ROSC prior to Ed admission (4), Time from ED admission (4), time duration ROSC to PICU (5). 502
Results expressed as Median (Inter-quartile range) or number (percent). Chi2 test or Fishers exact test was 503
used for categorical variable. b median value rounded up to nearest whole value.  c Only patients receiving CPR 504
at ED admission were included in calculation, Fishers exact test was used for categorical variable and Mann 505
Whitney U test for continuous variables. ** p value < 0.05 comparing treatment groups506
507
508
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Table 3 Survival outcomes in relationship to treatment groups508
Total Group
n =73
TTM
n=38
STM
n = 35
p
Outcome
Survival to PICU discharge 22 (30%) 14 (37%) 8 (23%) 0.19
Survival to Hospital discharge 21 (29%) 13 (34%) 8 (23%) 0.28
PICU Length of stay (LOS) (days) 3.1
(1.3-6.6)
4.1
(3.0-6.8)
1.3
(0.5-6.7)
<0.001
PICU LOS for survivors (days) 6.5
(2.9-7.6)
6.2
(3.0-7.8)
6.7
(0.9-8.1)
0.81
PICU LOS for non-survivors (days) 2.4
(0.8-4.7)
4.1
(2.6-5.2)
1.2
(0.4-2.4)
<0.001
Withdrawal of intensive care support 
(proportion of patients who died in 
PICU [n=51])
46 (90%) 24 (100%) 22 (81%) 0.31
Fulfilled brain death criteria
(proportion of patients who died in 
PICU [n=51])
9 (18) 5 (21%) 4 (15%) 0.73
Results expressed as Median (Inter-quartile range) or number (percent). LOS: length of stay. Fisher’s exact test 509
was used for categorical variable and Mann Whitney U test for continuous variables.510
511
512
513
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Figure 1 Percentage of patients receiving targeted temperature management (TTM) and standard 
temperature management (STM) 
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Dashed line indicates first publication date of ILCOR guidelines for paediatric TTM use: Published on-line April 
17th 2006 - “Induction of hypothermia (32 to 34°C) for 12 to 24 hours should be considered in children who 
remain comatose after resuscitation from cardiac arrest.” (37) 
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Figure 2 Temperature profiles of patients receiving targeted temperature management and standard 
temperature management. 
 
Mean temperature (with 95% confidence intervals for the mean). TTM: targeted temperature management 
(32-34°C).  STM: Standard temperature management (<38°C). 
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